PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate CYP-001 into phase II trials after reporting solid results in two cohorts of patients in its phase I trial in steroid-resistant graft-vs.-host disease.